When you look at the results, what do you think are the most important findings?

Compared to non-Asian, Asian patient was younger, substantially lighter, have worse renal function, and had higher rate of prior stroke and TIA.

And also the median TTR with warfarin was significantly lower in Asian.

On warfarin, Asians had significantly higher adjusted risks of stroke, systemic embolism, major bleeding, intracranial hemorrhage, and GI bleeding.

Compared to non-Asian, even after multivariable adjustment, these elevated risk persisted in subgroup with TTR more than 70%.

And importantly, standard dose DOAC reduced stroke, major bleeding, and primary clinical outcome to a significantly greater degree in Asians than non-Asian.

Notably, standard dose DOACs did not increase GI bleeding in Asians, whereas they did in non-Asian.

How does this study move the field forward compared with what we already knew?